EOLS News and Press, Evolus Inc. From 03/08/23

Q4 2022 Net Revenue Reached an All-Time High of $43.6 Million, Up 26% from Q4 2021 Full-Year 2022 Net Revenue of $148.6 Million, Up 49% Over 2021 Reaffirms Full-Year 2023 Net Revenue Guidance of $180 to $190 Million and Positive Non-GAAP Operating Income 1 in Q4 2023 ...

2023-03-07 17:35:20 ET Major earnings expected after the bell on Wednesday include: MongoDB ( MDB ) Asana ( ASAN ) Vermilion Energy ( VET ) Assertio Holdings ( ASRT ) Orion Office REIT ( ONL ) For further details see: Notable earnings afte...

Launch in second-largest European aesthetic toxin market 1 represents a significant step in company’s geographic expansion Novvia will serve as distribution partner in Germany and Austria Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-cent...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its fourth quarter and year end 2022 financial results and provide a business update on Wednesday, March 8, 2023, after the U...

No Effect on Manufacture, Export, Supply or Sale of Jeuveau ® or Nuceiva ® Settlement Agreement with Medytox Provided for Continued Manufacturing and Commercialization for Evolus Regardless of Any Litigation Between Medytox and Daewoong Evolus, Inc. (NASDAQ...

Evolus, Inc. ( NASDAQ: EOLS ) lost sharply in the morning hours Friday after its partner for Jeuveau Botox, Daewoong Pharmaceutical lost a civil lawsuit in Korea regarding the source of the latter's botulinum toxin (BTX) strain. As part of the ruling, the Seoul Central District Court ...

Summary Evolus' Jeuveau continues to see growth. Recent release of unaudited full-year 2022 financials showed revenues reaching $148.6 million, which was an increase of 49% over same period in 2021. It predicts that it will reach organic net revenue of $500 million by 2028. Interim ...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the SVB Securities Global Biopharma Conference. An audio webcast of this event w...

“Extra-strength” 40U formulation achieves one-point improvement on the Glabellar Lines Scale with the duration of effect lasting 26 weeks, representing a prolonged 6-month performance Results indicate a favorable safety profile; no serious adverse events reported and 88% of ...

Australia among the largest countries in the world for aesthetic neurotoxins 1 Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that the Australian Therapeutic Goods Administrati...